https://www.benzinga.com/general/biotech/23/10/35223055/novo-nordisks-kidney-outcomes-trial-has-broad-industry-implications
0
0
10/12/23 at 9:23am
Organization
Benzinga
Author
Adam Eckert
43 words
0
Comments
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on
You are the first to view
Create an account
or login to join the discussion